Starling Oncology, Inc. Selling, General and Administrative Expense
Starling Oncology, Inc. (DFPH) reported Selling, General and Administrative Expense of $29.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- Starling Oncology, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $29.94M, a 11.28% increase year-over-year.
- Starling Oncology, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $28.21M, a 11.18% increase year-over-year.
- Starling Oncology, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $28.04M, a 12.80% increase year-over-year.
- Starling Oncology, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $25.25M, a 5.24% decline year-over-year.
- Starling Oncology, Inc. selling, general and administrative expense for fiscal 2025 was $105.57M, a 2.09% decline from fiscal 2024.
- Starling Oncology, Inc. selling, general and administrative expense for fiscal 2024 was $107.83M, a 5.29% decline from fiscal 2023.
- Starling Oncology, Inc. selling, general and administrative expense for fiscal 2023 was $113.85M, a 4.88% decline from fiscal 2022.
- Starling Oncology, Inc. selling, general and administrative expense for fiscal 2022 was $119.69M, a 43.57% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.94M 10-Q · filed 2026-08-06 | $58.16M 10-Q · filed 2026-08-06 | $86.19M derived: sum of 3 quarters · filed 2026-08-06 | $111.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $28.21M 10-Q · filed 2026-05-07 | $56.25M derived: sum of 2 quarters · filed 2026-05-07 | $81.50M derived: sum of 3 quarters · filed 2026-05-07 | $108.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $28.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $53.29M derived: sum of 2 quarters · filed 2026-03-12 | $80.20M derived: sum of 3 quarters · filed 2026-08-06 | $105.57M 10-K · filed 2026-03-12 |
| 2025-09-30 | $25.25M 10-Q · filed 2025-11-13 | $52.16M derived: sum of 2 quarters · filed 2026-08-06 | $77.53M 10-Q · filed 2025-11-13 | $102.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $26.91M 10-Q · filed 2026-08-06 | $52.28M 10-Q · filed 2025-08-13 | $77.14M derived: sum of 3 quarters · filed 2026-08-06 | $103.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $25.38M 10-Q · filed 2026-05-07 | $50.23M derived: sum of 2 quarters · filed 2026-05-07 | $76.88M derived: sum of 3 quarters · filed 2026-05-07 | $104.75M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $24.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $51.50M derived: sum of 2 quarters · filed 2026-03-12 | $79.38M derived: sum of 3 quarters · filed 2026-03-12 | $107.83M 10-K · filed 2026-03-12 |
| 2024-09-30 | $26.65M 10-Q · filed 2025-11-13 | $54.52M derived: sum of 2 quarters · filed 2025-11-13 | $82.97M 10-Q · filed 2025-11-13 | $111.06M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $27.87M 10-Q · filed 2025-08-13 | $56.32M 10-Q · filed 2025-08-13 | $84.41M derived: sum of 3 quarters · filed 2025-08-13 | $112.62M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $28.45M 10-Q · filed 2025-05-14 | $56.54M derived: sum of 2 quarters · filed 2025-05-14 | $84.75M derived: sum of 3 quarters · filed 2025-05-14 | $113.47M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $28.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $56.30M derived: sum of 2 quarters · filed 2025-03-26 | $85.02M derived: sum of 3 quarters · filed 2025-03-26 | $113.85M 10-K · filed 2025-03-26 |
| 2023-09-30 | $28.20M 10-Q · filed 2024-11-13 | $56.93M derived: sum of 2 quarters · filed 2024-11-13 | $85.76M 10-Q · filed 2024-11-13 | $115.33M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $28.73M 10-Q · filed 2024-08-13 | $57.56M 10-Q · filed 2024-08-13 | $87.13M derived: sum of 3 quarters · filed 2024-08-13 | $119.09M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $28.83M 10-Q · filed 2024-05-14 | $58.40M derived: sum of 2 quarters · filed 2024-05-14 | $90.36M derived: sum of 3 quarters · filed 2024-05-14 | $118.71M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $29.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $61.53M derived: sum of 2 quarters · filed 2024-03-28 | $89.88M derived: sum of 3 quarters · filed 2024-03-28 | $119.69M 10-K · filed 2024-03-28 |
| 2022-09-30 | $31.96M 10-Q · filed 2023-11-08 | $60.31M derived: sum of 2 quarters · filed 2023-11-08 | $90.12M 10-Q · filed 2023-11-08 | $138.36M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $28.35M 10-Q · filed 2023-08-09 | $58.15M 10-Q · filed 2023-08-09 | $106.40M derived: sum of 3 quarters · filed 2023-08-09 | $119.13M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $29.81M 10-Q · filed 2023-05-10 | $78.05M derived: sum of 2 quarters · filed 2023-05-10 | $90.78M derived: sum of 3 quarters · filed 2023-05-10 | $101.99M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $48.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $60.98M derived: sum of 2 quarters · filed 2023-03-16 | $72.19M derived: sum of 3 quarters · filed 2023-03-16 | $83.36M 10-K · filed 2023-03-16 |
| 2021-09-30 | $12.73M 10-Q · filed 2022-11-09 | $23.94M derived: sum of 2 quarters · filed 2022-11-09 | $35.12M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $11.21M 10-Q · filed 2022-08-09 | $22.39M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $11.18M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $41.90M 10-K · filed 2022-03-11 |